Fig. 2From: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization studyChange in LDLC from entry to 28, 42, and 52 weeks on Alirocumab 150 mg (n = 18) and Evolocumab 140 mg (n = 22) every 2 weeks (data pooled); median, 25th and 75th LDLC percentiles displayedBack to article page